Cancer Cachexia Market Size Worth $3.43 Billion By 2032 | CAGR: 4.2%

The global cancer cachexia market size is expected to reach USD 3.43 billion by 2032, according to a new study by Polaris Market Research. The report “Cancer Cachexia Market Share, Size, Trends, Industry Analysis Report, By Therapeutics (Progestogens, Corticosteroids, Combination Therapy, and Others); By Mechanism of Action; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The drastic increase in the prevalence of cancer, especially among the geriatric population, and growing awareness among healthcare professionals about the significance of cachexia contribute to the global market growth. With the increase in cancer patients, the risk of developing cancer cachexia among individuals also rises.

For instance, according to the GLOBOCAN 2022 data, more than 53% of people who had cancer in 2022 were aged 65 years or above. As the world’s ageing population is growing rapidly, with 760 million people in 2022, and is expected to rise to 1.6 billion people by 2050, the prevalence of cancer is also likely to increase.

A growing number of government initiatives supporting cancer research and promoting the development of advanced therapies and drugs also propelled the market’s growth. There are key pharmaceutical companies involved in the development of new novel therapies that are specifically developed for addressing cancer cachexia.

For instance, in August 2023, Actimed Therapeutics, announced that they have raised £4.75 million for the treatment of cancer cachexia and many other muscle wasting disorders. The fund will be utilized to continue the development of the company and ensure the preparation of the IMPACT clinical development program.

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below: https://www.polarismarketresearch.com/industry-analysis/cancer-cachexia-market/request-for-sample 

Cancer remains the leading cause of death for people between the ages of 40-79 years old, and 80% of cancer cases are associated with cachexia, and approx. 20% of patients die due to cancer cachexia; there is a significant need for further studies regarding its complex condition and the development of targeted therapies that are aimed at the specific molecular pathways associated with cachexia.

For instance, in September 2023, Actimed Therapeutics, announced that they have received approval from US FDA for their IND application for Phase 2b/3 clinical study of the S-pindolol benzoate for the treatment of cachexia that are associated with patients with non-small cell lung cancer.

Cancer Cachexia Market Report Highlights

• The Progestogens segment accounted for a notable share in 2023, on account of its greater efficiency in treatment and the presence of anti-inflammatory properties.
• Appetite stimulators segment held the majority share in 2023, which is attributed to its widespread adoption by cancer patients for maintaining body shape and mass.
• The online pharmacy segment categorized under the distribution channel is predicted to grow at the highest CAGR during the forecast period due to the growing popularity of online pharmacies due to its features like prescription management and time-saving.
• North America dominated the global market, owing to the presence of well-established healthcare infrastructure and the significant prevalence of cancer.
• The key market players include Aeterna Zentaris, ANI Pharmaceuticals, Merck & Co. Inc., TCI Peptide Therapeutics, and Teva Pharmaceutical Industries.

Polaris Market Research has segmented the cancer cachexia market report based on therapeutics, mechanism of action, distribution channel, and region:

Cancer Cachexia, Therapeutics Outlook (Revenue - USD Billion, 2024 - 2032)

• Progestogens
• Corticosteroids
• Combination Therapy
• Others

Cancer Cachexia, Mechanism of Action Outlook (Revenue - USD Billion, 2024 - 2032)

• Appetite Stimulators
• Weight Loss Stabilizers

Cancer Cachexia, Distribution Channel Outlook (Revenue - USD Billion, 2024 - 2032)

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Cancer Cachexia, Regional Outlook (Revenue - USD Billion, 2024 - 2032)

• North America

• U.S.
• Canada

• Europe

• Germany
• UK
• France
• Italy
• Spain
• Russia
• Netherlands
• Rest of Europe

• Asia Pacific

• China
• India
• Japan
• South Korea
• Indonesia
• Malaysia
• Australia
• Rest of Asia Pacific

• Latin America

• Argentina
• Brazil
• Mexico
• Rest of Latin America

• Middle East & Africa

• UAE
• Saudi Arabia
• Israel
• South Africa
• Rest of Middle East and Africa

Cancer Cachexia Market Report Scope